Autolus Therapeutics (AUTL) Stock: 35.47% Increase Explanation

By Amit Chowdhry ● May 12, 2021
  • The stock price of Autolus Therapeutics (NASDAQ: AUTL) increased by 35.47% today. This is why it happened.

The stock price of Autolus Therapeutics (NASDAQ: AUTL) – a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies – increased by over 30% during intraday trading today. Investors appear to be responding positively to Autolus Therapeutics announcing an abstract presentation related to AUTO1 in relapsed / refractory (r/r) indolent B cell lymphomas (IBCL) at the European Hematology Association (EHA) Virtual Congress to be held June 9-17, 2021.

These are the details:

— Title: Early safety and efficacy findings of AUTO1 (CAT19), a fast-off rate CD19 CAR, in Relapsed/Refractory Indolent B Cell Lymphomas

— Presenter: Clare Roddie, MD, PhD, FRCPath, Consultant Haematologist and Honorary Senior Lecturer, Cancer Institute, University College London (UCL)

— Date and Time: All e-poster presentations will be made available on the on-demand Virtual Congress platform as of Friday, June 11 at 9.00 AM CEST.

As of the data cut-off date of February 18, 2021, 10 r/r IBCL patients had received AUTO1 and nine patients were evaluable. And AUTO1 demonstrated a tolerable safety profile in adult patients with r/r low grade B-cell lymphoma despite high disease burden.

The early data shows 100% complete remission rates and excellent CAR engraftment and expansion. 

The Grade 1 CRS was reported in 4 patients and Grade 2 CRS in 1 patient. No Immune effector cell-associated neurotoxicity syndrome (ICANS) was observed on the study. At a median of 3.1 months (range 1-5.6m), 8/9 patients are in ongoing remission. And one patient died in complete remission at month 5.6 of COVID-19.

Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.